Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GSK Plc

Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK

Ideaya Biosciences Inc (NASDAQ:IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate, a small molecule inhibitor of the helicase domain of DNA Polymerase Theta. Ideaya is collaborating with GSK plc (NYSE:GSK) on IND-enabling studies to support the evaluation of the Pol Theta Helicase candidate in combination with niraparib, GSK's PARP inhibitor, in tumors with…

GSK Shares Encouraging Data From Chronic Hepatitis B Candidate

GSK Shares Encouraging Data From Chronic Hepatitis B Candidate

GSK plc (NYSE:GSK) announced promising interim results from the B-Clear phase 2b trial of bepirovirsen in people with chronic hepatitis B (CHB). The data showed that bepirovirsen reduced hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA after 24 weeks of treatment. In the group of 227 patients on standard…

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Antibiotic Makers Adopt Their Own Environmental Safeguard Standards

The AMR Industry Alliance, a life-sciences coalition set up to provide sustainable solutions to curb antimicrobial resistance (AMR), is adopting its standards limiting toxic emissions. The Alliance published its Antibiotic Manufacturing Standard: Minimizing the risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from manufacturing human antibiotics. The…

GSK Shows Positive Pivotal Phase III Data For Its RSV Vaccine Candidate

GSK plc (NYSE:GSK) intends to engage with regulators immediately after reporting positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial, it anticipates regulatory submissions in the second half of 2022. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate…

Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off

Pfizer Inc. (NYSE:PFE) intends to sell its 32% investment in Haleon, a consumer health joint venture with GSK plc (NYSE:GSK), after the business is spun out as an independent listed company in July, reported Reuters. Pfizer had previously indicated that it might seek to sell its stake in Haleon, a consumer health company and…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

London Stock Exchange

European Medicines Agency

IDEAYA Biosciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

249,789 stories

106,171 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play